{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:23:40Z","timestamp":1787027020719,"version":"build-2736575974"},"reference-count":139,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Recent insight in the genomic landscape of newly diagnosed multiple myeloma (NDMM) and its precursor conditions, monoclonal gammopathy of uncertain significance (MGUS), and smoldering myeloma have allowed the identification of patients with precursor conditions with a high risk of progression. These cases with \u201cprogressor\u201d MGUS\/SMM have a higher average mutation burden, have higher rates of mutations in specific genes such as MAPK, DNA repair,\n                    <jats:italic>MYC<\/jats:italic>\n                    ,\n                    <jats:italic>DIS3<\/jats:italic>\n                    , and are enriched for specific mutational signatures when compared to non-progressors and are comparable to those found in NDMM. The highly preserved clonal heterogeneity seen upon progression of SMM, combined with the importance of these early variables, suggests that the identification of progressors based on these findings could complement and enhance the currently available clinical models based on tumor burden. Mechanisms leading to relapse\/refractory multiple myeloma (RRMM) are of clinical interest given worse overall survival in this population. An Increased mutational burden is seen in patients with RRMM when compared to NDMM, however, there is evidence of branching evolution with many of these mutations being present at the subclonal level. Likewise, alterations in proteins associated with proteosome inhibitor and immunomodulatory drugs activity could partially explain clinical resistance to these agents. Evidence of chromosomal events leading to copy number changes is seen, with the presence of\n                    <jats:italic>TP53<\/jats:italic>\n                    deletion, mutation, or a combination of both being present in many cases. Additional chromosomal events such as 1q gain and amplification may also interact and lead to resistance.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2022.1020011","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:44:21Z","timestamp":1666831461000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance"],"prefix":"10.3389","volume":"12","author":[{"given":"Mateo","family":"Mejia Saldarriaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walaa","family":"Darwiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jayabalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Monge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Rosenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger N.","family":"Pearse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Niesvizky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bustoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"key":"B1","unstructured":"Myeloma \u2014 cancer stat facts. published march 16, 2022"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2010-07-298760","article-title":"Racial disparities in incidence and outcome in multiple myeloma: a population-based study","volume":"116","author":"Waxman","year":"2010","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.11.013","article-title":"Multiple myeloma in hispanics: Incidence, characteristics, survival, results of discovery, and validation using real-world and connect MM registry data","volume":"21","author":"Kaur","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"B4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1023\/A:1022268103136","article-title":"Myeloma and race: a review of the literature","volume":"22","author":"Benjamin","year":"2003","journal-title":"Cancer Metastasis Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/leu.2016.380","article-title":"Trends in overall survival and costs of multiple myeloma, 2000\u20132014","volume":"31","author":"Fonseca","year":"2017","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2005-08-3449","article-title":"Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the united states","volume":"107","author":"Landgren","year":"2006","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma","volume":"302","author":"Kyle","year":"1980","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International myeloma working group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e454","DOI":"10.1038\/bcj.2016.65","article-title":"Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma","volume":"6","author":"Ravi","year":"2016","journal-title":"Blood Cancer J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0013-4","article-title":"Evolving m-protein pattern in patients with smoldering multiple myeloma: Impact on early progression","volume":"32","author":"de Larrea","year":"2018","journal-title":"Leukemia"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00437","article-title":"Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression","volume":"38","author":"Bustoros","year":"2020","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00474-8","article-title":"Chromosome 1q21 abnormalities in multiple myeloma","volume":"11","author":"Schmidt","year":"2021","journal-title":"Blood Cancer J"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational spectrum, copy number changes, and outcome: Results of a sequencing study of patients with newly diagnosed myeloma","volume":"33","author":"Walker","year":"2015","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-20524-2","article-title":"The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma","volume":"12","author":"Boyle","year":"2021","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0543-4","article-title":"MYC dysregulation in the progression of multiple myeloma","volume":"34","author":"Misund","year":"2020","journal-title":"Leukemia"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/J.CCR.2013.12.015\/ATTACHMENT\/F8CA6BBE-57E7-46FB-840C-20C0C12E93BA\/MMC10.XLSX","article-title":"Widespread genetic heterogeneity in multiple myeloma: Implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"key":"B26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/J.CELL.2010.11.055\/ATTACHMENT\/F05F620E-45EC-41D3-81B9-1AFB409EE44F\/MMC6.PDF","article-title":"Massive genomic rearrangement acquired in a single catastrophic event during cancer development","volume":"144","author":"Stephens","year":"2011","journal-title":"Cell"},{"key":"B27","doi-asserted-by":"publisher","first-page":"7793","DOI":"10.1038\/s41586-019-1913-9","article-title":"Patterns of somatic structural variation in human cancer genomes","volume":"578","author":"Li","year":"2020","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-20-0132","article-title":"Revealing the impact of structural variants in multiple myeloma","volume":"1","author":"Rustad","year":"2020","journal-title":"Blood Cancer Discov"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-344069","article-title":"Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients","volume":"118","author":"Magrangeas","year":"2011","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22140-0","article-title":"Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities","volume":"12","author":"Oben","year":"2021","journal-title":"Nat Commun"},{"key":"B31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/ng.3441","article-title":"Clock-like mutational processes in human somatic cells","volume":"47","author":"Alexandrov","year":"2015","journal-title":"Nat Genet"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2009-12-261032","article-title":"Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients","volume":"116","author":"Broyl","year":"2010","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30694-w","article-title":"Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes","volume":"13","author":"Bustoros","year":"2022","journal-title":"Nat Commun"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2016-06-723007","article-title":"Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma","volume":"128","author":"Weinhold","year":"2016","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3324\/HAEMATOL.2021.278888","article-title":"Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients","volume":"106","author":"Weinhold","year":"2021","journal-title":"Haematologica."},{"key":"B37","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1182\/BLOOD-2020-137060","article-title":"Impact of gain and amplification of 1q in newly diagnosed multiple myeloma patients receiving carfilzomib-based treatment in the forte trial","volume":"136","author":"D\u2019Agostino","year":"2020","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00535-0\/ATTACHMENT\/3D490F77-13D8-475C-AEC6-5D03249A3F62\/MMC2.PDF","article-title":"Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/J.ANNONC.2020.02.018\/ATTACHMENT\/8FD9C8AD-B48C-472C-8302-DCF911D402B8\/MMC1.DOCX","article-title":"Acute myeloid leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020","volume":"31","author":"Heuser","year":"2020","journal-title":"Ann Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-0043-5","article-title":"Circulating tumor DNA and liquid biopsy in oncology","volume":"1","author":"Cescon","year":"2020","journal-title":"Nat Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/EJH.13541","article-title":"Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA","volume":"106","author":"Deshpande","year":"2021","journal-title":"Eur J Haematol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-021-01492-y","article-title":"Cell-free DNA for the detection of emerging treatment failure in relapsed\/ refractory multiple myeloma","volume":"2022","author":"Waldschmidt","year":"2021","journal-title":"Leukemia"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2021-146535","article-title":"Circulating tumor cells (CTCs) in smoldering and active multiple myeloma (MM): Mechanism of egression, clinical significance and therapeutic endpoints","volume":"138","author":"Garc\u00e9s","year":"2021","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/BJH.13067","article-title":"Quantification of clonal circulating plasma cells in relapsed multiple myeloma","volume":"167","author":"Gonsalves","year":"2014","journal-title":"Br J Haematol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2005-05-1858","article-title":"Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma","volume":"106","author":"Nowakowski","year":"2005","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/S41375-020-0883-0","article-title":"Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma","volume":"34","author":"Garc\u00e9s","year":"2020","journal-title":"Leukemia"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/LEU.2016.205","article-title":"Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression","volume":"31","author":"Gonsalves","year":"2017","journal-title":"Leukemia"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41408-018-0153-9","article-title":"Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)","volume":"8","author":"Sanoja-Flores","year":"2018","journal-title":"Blood Cancer J"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/NRCLINONC.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.828351","article-title":"The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma","volume":"55","author":"Manasanch","year":"2014","journal-title":"Leuk Lymphoma."},{"key":"B52","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/J.CCR.2013.08.009","article-title":"Xbp1s-negative tumor b cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma","volume":"24","author":"Leung-Hagesteijn","year":"2013","journal-title":"Cancer Cell"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/J.LEUKRES.2011.09.011","article-title":"Bortezomib resistance in a myeloma cell line is associated to PSM\u03b25 overexpression and polyploidy","volume":"36","author":"Balsas","year":"2012","journal-title":"Leuk Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/S41375-018-0216-8","article-title":"Spectrum and functional validation of PSMB5 mutations in multiple myeloma","volume":"33","author":"Barrio","year":"2019","journal-title":"Leukemia."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.7554\/ELIFE.08153","article-title":"Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits","volume":"4","author":"Acosta-Alvear","year":"2015","journal-title":"Elife"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/BJH.12291","article-title":"Extramedullary myeloma whole genome sequencing reveals novel mutations in cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease","volume":"161","author":"Egan","year":"2013","journal-title":"Br J Haematol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2012-03-412981","article-title":"Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma","volume":"120","author":"Walker","year":"2012","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2016-02-698092","article-title":"Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and ras pathway genes","volume":"128","author":"Kort\u00fcm","year":"2016","journal-title":"Blood"},{"key":"B59","article-title":"Blockade of Hsp27 overcomes bortezomib\/proteasome inhibitor PS-341 resistance in lymphoma cells","volume":"63","author":"Chauhan","year":"2003","journal-title":"Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2011-10-386789","article-title":"Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma","volume":"120","author":"Kuhn","year":"2012","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-02167-9","article-title":"Deubiquitylase USP12 induces pro-survival autophagy and bortezomib resistance in multiple myeloma by stabilizing HMGB1","volume":"41","author":"Li","year":"2022","journal-title":"Oncogene"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11059","article-title":"Comparative proteomic profiling of refractory\/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy","volume":"7","author":"Dytfeld","year":"2016","journal-title":"Oncotarget"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"897","DOI":"10.4065\/75.9.897","article-title":"Thalidomide in the treatment of relapsed multiple myeloma","volume":"75","author":"Vincent Rajkumar","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2002-03-0996","article-title":"Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1046\/J.1365-2249.2002.01954.X","article-title":"Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells","volume":"130","author":"Marriott","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2003-02-0361","article-title":"Immunomodulatory drug costimulates T cells via the B7-CD28 pathway","volume":"103","author":"LeBlanc","year":"2004","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.14735\/AMKO2014326","article-title":"Cereblon - a new target of therapy in the treatment of multiple myeloma","volume":"27","author":"Stankov\u00e1","year":"2014","journal-title":"Klin Onkol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1126\/SCIENCE.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1126\/SCIENCE.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1111\/BJH.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors ikaros and aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.)","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br J Haematol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/LEU.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.4049\/JIMMUNOL.179.11.7305","article-title":"Ikaros enforces the costimulatory requirement for IL2 gene expression and is required for anergy induction in CD4+ T lymphocytes","volume":"179","author":"Thomas","year":"2007","journal-title":"J Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12157","article-title":"Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner","volume":"12","author":"Dimopoulos","year":"2018","journal-title":"Mol Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/LEU.2014.238","article-title":"In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone","volume":"29","author":"Ocio","year":"2015","journal-title":"Leukemia."},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1111\/CAS.14352","article-title":"Expression, mutation, and methylation of cereblon-pathway genes at pre- and post-lenalidomide treatment in multiple myeloma","volume":"111","author":"Tachita","year":"2020","journal-title":"Cancer Sci"},{"key":"B78","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/BJH.13905","article-title":"Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma","volume":"172","author":"Rychak","year":"2016","journal-title":"Br J Haematol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1485915","article-title":"Cereblon gene expression and correlation with clinical outcomes in patients with relapsed\/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS","volume":"60","author":"Qian","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/S41375-021-01373-4","article-title":"Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs","volume":"35","author":"Jones","year":"2021","journal-title":"Leukemia"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1074\/JBC.M117.816868","article-title":"Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon","volume":"293","author":"Akuffo","year":"2018","journal-title":"J Biol Chem"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2020007081","article-title":"Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma","volume":"137","author":"Gooding","year":"2021","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.V128.22.120.120","article-title":"Cereblon splicing of exon 10 mediates IMiDs resistance in multiple myeloma: Clinical validation in the CoMMpass trial","volume":"128","author":"Neri","year":"2016","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1152\/PHYSREV.00035.2007","article-title":"Evolution and function of the ADP ribosyl cyclase\/CD38 gene family in physiology and pathology","volume":"88","author":"Malavasi","year":"2008","journal-title":"Physiol Rev"},{"key":"B86","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/BLOOD-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3324\/HAEMATOL.2018.194282","article-title":"Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX","volume":"103","author":"Dimopoulos","year":"2018","journal-title":"Haematologica"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3324\/HAEMATOL.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2018.02134","article-title":"CD38 antibodies in multiple myeloma: Mechanisms of action and modes of resistance","volume":"9","author":"van de Donk","year":"2018","journal-title":"Front Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1111\/EJH.12902","article-title":"CD38-negative relapse in multiple myeloma after daratumumab-based chemotherapy","volume":"99","author":"Minarik","year":"2017","journal-title":"Eur J Haematol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/J.CLML.2016.02.037","article-title":"Loss of CD38 expression in relapsed refractory multiple myeloma","volume":"16","author":"Ise","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2027","article-title":"Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab","volume":"23","author":"Krejcik","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/LEU.2015.123","article-title":"Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab","volume":"29","author":"Nijhof","year":"2015","journal-title":"Leukemia"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1182\/BLOODADVANCES.2021005220","article-title":"Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed\/refractory multiple myeloma","volume":"5","author":"Frerichs","year":"2021","journal-title":"Blood Adv"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2017-03-770776","article-title":"Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab","volume":"129","author":"Garc\u00eda-Guerrero","year":"2017","journal-title":"Blood"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2019004332","article-title":"The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications","volume":"136","author":"Ogiya","year":"2020","journal-title":"Blood"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3324\/HAEMATOL.2015.139667","article-title":"Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance","volume":"101","author":"de Haart","year":"2016","journal-title":"Haematologica"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.V122.21.4447.4447","article-title":"Evaluation of bcma as a therapeutic target in multiple myeloma using an antibody-drug conjugate","volume":"122","author":"Yong","year":"2013","journal-title":"Blood"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2003-06-2043","article-title":"Expression of BCMA, TACI, and BAFF-r in multiple myeloma: a mechanism for growth and survival","volume":"103","author":"Novak","year":"2004","journal-title":"Blood"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/S41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nat Med"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/S41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/NCOMMS8333","article-title":"\u03b3-secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat Commun"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/J.LEUKRES.2019.04.008","article-title":"Serum b-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells","volume":"81","author":"Chen","year":"2019","journal-title":"Leuk Res"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1111\/BJH.16752","article-title":"Normalization of serum b-cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment","volume":"192","author":"Jew","year":"2021","journal-title":"Br J Haematol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3324\/HAEMATOL.2016.150896","article-title":"Serum b-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients","volume":"102","author":"Ghermezi","year":"2017","journal-title":"Haematologica"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/S41408-021-00505-4","article-title":"Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients","volume":"11","author":"Visram","year":"2021","journal-title":"Blood Cancer J"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/NM.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/S41375-018-0374-8","article-title":"Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma","volume":"33","author":"Matulis","year":"2019","journal-title":"Leukemia"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/LEU.2013.216","article-title":"The bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma","volume":"28","author":"Touzeau","year":"2014","journal-title":"Leukemia"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1111\/JPHP.13240","article-title":"Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma","volume":"72","author":"Wong","year":"2020","journal-title":"J Pharm Pharmacol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1038\/S41375-019-0421-0","article-title":"BCL2 blockade overcomes MCL1 resistance in multiple myeloma","volume":"33","author":"Siu","year":"2019","journal-title":"Leukemia"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3324\/HAEMATOL.2021.278506","article-title":"mTOR inhibitors sensitize multiple myeloma cells to venetoclax via IKZF3- and blimp-1-mediated BCL-2 upregulation","volume":"106","author":"Osada","year":"2021","journal-title":"Haematologica"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2020007899","article-title":"Venetoclax sensitivity in multiple myeloma is associated with b-cell gene expression","volume":"137","author":"Gupta","year":"2021","journal-title":"Blood"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS13194898","article-title":"Transcriptomic analysis in multiple myeloma and primary plasma cell leukemia with t(11;14) reveals different expression patterns with biological implications in venetoclax sensitivity","volume":"13","author":"Todoerti","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0730","article-title":"Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models","volume":"15","author":"Punnoose","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2018-03-836718","article-title":"BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment","volume":"132","author":"Gomez-Bougie","year":"2018","journal-title":"Blood"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1182\/BLOODADVANCES.2019000702","article-title":"Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting","volume":"3","author":"Slomp","year":"2019","journal-title":"Blood Adv"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3324\/HAEMATOL.2018.212308","article-title":"Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma","volume":"105","author":"Algar\u00edn","year":"2020","journal-title":"Haematologica"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/S41419-020-2505-1","article-title":"Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX\/BAK hetero-complexes","volume":"11","author":"Seiller","year":"2020","journal-title":"Cell Death Dis"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS13184668","article-title":"Multiple myeloma relapse is associated with increased NF\u03baB pathway activity and upregulation of the pro-survival BCL-2 protein BFL-1","volume":"13","author":"Spaan","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1002\/AJH.26064","article-title":"Natural history of multiple myeloma patients refractory to venetoclax: A single center experience","volume":"96","author":"Maples","year":"2021","journal-title":"Am J Hematol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/S41467-020-15051-Z","article-title":"Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma","volume":"11","author":"Bajpai","year":"2020","journal-title":"Nat Commun"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2017-06-788323","article-title":"Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0676","article-title":"Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells","volume":"65","author":"Qin","year":"2005","journal-title":"Cancer Res"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1038\/LEU.2015.350","article-title":"Dexamethasone treatment promotes bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax","volume":"30","author":"Matulis","year":"2016","journal-title":"Leukemia"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1007\/S00277-021-04555-3","article-title":"Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed\/refractory multiple myeloma patients-a single-center retrospective study","volume":"100","author":"Regidor","year":"2021","journal-title":"Ann Hematol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00443","article-title":"Phase I study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib, in patients with relapsed or refractory multiple myeloma with and without t(11;14)","volume":"39","author":"Bahlis","year":"2021","journal-title":"J Clin Oncol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-00442-4","article-title":"The nuclear export protein XPO1 \u2014 from biology to targeted therapy","volume":"18","author":"Azmi","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): A randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2018-99-116500","article-title":"E2F1 is a biomarker of selinexor resistance in Relapsed\/Refractory multiple myeloma patients","volume":"132","author":"Lagana","year":"2018","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1020011\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:44:27Z","timestamp":1666831467000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1020011\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":139,"alternative-id":["10.3389\/fonc.2022.1020011"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1020011","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,27]]},"article-number":"1020011"}}